阿尔茨海默病的诊疗规范(2020年版)

2021-01-30 中华人民共和国国家卫生健康委员会 全科医学临床与教育.2021.19(1):4-6.

阿尔茨海默病是一种起病隐袭、呈进行性发展的神经退行性疾病,临床特征主要为认知障碍、精神行为异常和社会生活功能减退。一般在65 岁以前发病为早发型,65 岁以后发病为晚发型,有家族发病倾向被称为家族性阿

中文标题:

阿尔茨海默病的诊疗规范(2020年版)

发布日期:

2021-01-30

简要介绍:

阿尔茨海默病是一种起病隐袭、呈进行性发展的神经退行性疾病,临床特征主要为认知障碍、精神行为异常和社会生活功能减退。一般在65 岁以前发病为早发型,65 岁以后发病为晚发型,有家族发病倾向被称为家族性阿尔茨海默病,无家族发病倾向被称为散发性阿尔茨海默病。据世界卫生组织报告,目前全球约有5000 万人患有痴呆症,其中阿尔茨海默病是最常见的类型。阿尔茨海默病可能的危险因素包括:增龄、女性、低教育水平、吸烟、中年高血压与肥胖、听力损害、脑外伤、缺乏锻炼、社交孤独、糖尿病及抑郁障碍等。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=阿尔茨海默病的诊疗规范_2020年版_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9320b1c00206e2b7, title=阿尔茨海默病的诊疗规范(2020年版), enTitle=, guiderFrom=全科医学临床与教育.2021.19(1):4-6., authorId=0, author=, summary=阿尔茨海默病是一种起病隐袭、呈进行性发展的神经退行性疾病,临床特征主要为认知障碍、精神行为异常和社会生活功能减退。一般在65 岁以前发病为早发型,65 岁以后发病为晚发型,有家族发病倾向被称为家族性阿, cover=https://img.medsci.cn/202138/1615138255495_2020535.jpg, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Sat Jan 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>阿尔茨海默病是一种起病隐袭、呈进行性发展的神经退行性疾病,临床特征主要为认知障碍、精神行为异常和社会生活功能减退。一般在65 岁以前发病为早发型,65 岁以后发病为晚发型,有家族发病倾向被称为家族性阿尔茨海默病,无家族发病倾向被称为散发性阿尔茨海默病。据世界卫生组织报告,目前全球约有5000 万人患有痴呆症,其中阿尔茨海默病是最常见的类型。阿尔茨海默病可能的危险因素包括:增龄、女性、低教育水平、吸烟、中年高血压与肥胖、听力损害、脑外伤、缺乏锻炼、社交孤独、糖尿病及抑郁障碍等。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=787, tagName=阿尔茨海默病)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=19, categoryName=老年医学, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=787, guiderKeyword=阿尔茨海默病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=35569, appHits=923, showAppHits=0, pcHits=3673, showPcHits=34645, likes=7, shares=80, comments=46, approvalStatus=1, publishedTime=Mon Mar 08 01:49:10 CST 2021, publishedTimeString=2021-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 08 01:31:05 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:13:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=阿尔茨海默病的诊疗规范_2020年版_.pdf)])
阿尔茨海默病的诊疗规范_2020年版_.pdf
下载请点击:
评论区 (40)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2102380, encodeId=0cd9210238010, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Thu Nov 24 11:03:40 CST 2022, time=2022-11-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2089534, encodeId=a1d320895342b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb595551149, createdName=ms3000000908223949, createdTime=Wed Sep 21 13:32:01 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229084, encodeId=57aa1229084bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Tue Jun 28 08:27:15 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214964, encodeId=4473121496428, content=学到了,谢谢分享!!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fa8137814, createdName=ms6000000736877413, createdTime=Wed Apr 27 09:01:37 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081844, encodeId=26c01081844be, content=值得学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/367424541956415d9bef72d82653cd8a/7fa4a16fc4954a16a180098fb0391ee6.jpg, createdBy=c8cf5532779, createdName=jianhe, createdTime=Sun Dec 19 17:47:31 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-11-24 ms3000000771933475 来自吉林省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2102380, encodeId=0cd9210238010, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Thu Nov 24 11:03:40 CST 2022, time=2022-11-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2089534, encodeId=a1d320895342b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb595551149, createdName=ms3000000908223949, createdTime=Wed Sep 21 13:32:01 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229084, encodeId=57aa1229084bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Tue Jun 28 08:27:15 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214964, encodeId=4473121496428, content=学到了,谢谢分享!!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fa8137814, createdName=ms6000000736877413, createdTime=Wed Apr 27 09:01:37 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081844, encodeId=26c01081844be, content=值得学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/367424541956415d9bef72d82653cd8a/7fa4a16fc4954a16a180098fb0391ee6.jpg, createdBy=c8cf5532779, createdName=jianhe, createdTime=Sun Dec 19 17:47:31 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-09-21 ms3000000908223949

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2102380, encodeId=0cd9210238010, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Thu Nov 24 11:03:40 CST 2022, time=2022-11-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2089534, encodeId=a1d320895342b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb595551149, createdName=ms3000000908223949, createdTime=Wed Sep 21 13:32:01 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229084, encodeId=57aa1229084bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Tue Jun 28 08:27:15 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214964, encodeId=4473121496428, content=学到了,谢谢分享!!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fa8137814, createdName=ms6000000736877413, createdTime=Wed Apr 27 09:01:37 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081844, encodeId=26c01081844be, content=值得学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/367424541956415d9bef72d82653cd8a/7fa4a16fc4954a16a180098fb0391ee6.jpg, createdBy=c8cf5532779, createdName=jianhe, createdTime=Sun Dec 19 17:47:31 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-06-28 liuyingying35

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2102380, encodeId=0cd9210238010, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Thu Nov 24 11:03:40 CST 2022, time=2022-11-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2089534, encodeId=a1d320895342b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb595551149, createdName=ms3000000908223949, createdTime=Wed Sep 21 13:32:01 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229084, encodeId=57aa1229084bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Tue Jun 28 08:27:15 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214964, encodeId=4473121496428, content=学到了,谢谢分享!!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fa8137814, createdName=ms6000000736877413, createdTime=Wed Apr 27 09:01:37 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081844, encodeId=26c01081844be, content=值得学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/367424541956415d9bef72d82653cd8a/7fa4a16fc4954a16a180098fb0391ee6.jpg, createdBy=c8cf5532779, createdName=jianhe, createdTime=Sun Dec 19 17:47:31 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-04-27 ms6000000736877413

    学到了,谢谢分享!!!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2102380, encodeId=0cd9210238010, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Thu Nov 24 11:03:40 CST 2022, time=2022-11-24, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2089534, encodeId=a1d320895342b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb595551149, createdName=ms3000000908223949, createdTime=Wed Sep 21 13:32:01 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229084, encodeId=57aa1229084bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/d028dd72803b466fbec4fbb95fb69ab8/36dc5ab269ac424d983ff54da9dc4e15.jpg, createdBy=37881573320, createdName=liuyingying35, createdTime=Tue Jun 28 08:27:15 CST 2022, time=2022-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214964, encodeId=4473121496428, content=学到了,谢谢分享!!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fa8137814, createdName=ms6000000736877413, createdTime=Wed Apr 27 09:01:37 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081844, encodeId=26c01081844be, content=值得学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210625/367424541956415d9bef72d82653cd8a/7fa4a16fc4954a16a180098fb0391ee6.jpg, createdBy=c8cf5532779, createdName=jianhe, createdTime=Sun Dec 19 17:47:31 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2021-12-19 jianhe

    值得学习!

    0

拓展阅读

2016 阿尔茨海默病创新药物临床试验中国专家共识

中国神经内科相关专家小组(统称) · 2016-02-29

2018中国痴呆与认知障碍诊治指南(二):阿尔茨海默病诊治指南

中国医师协会神经内科医师分会 · 2018-04-03

阿尔茨海默病的中医诊疗共识

中华中医药学会(CACM,China Association of Chinese Medcine) 脑病分会 · 2018-05-02

2018中国痴呆与认知障碍诊治指南(六):阿尔茨海默病痴呆前阶段

中国医师协会神经内科医师分会 · 2018-05-22